如何選定研究主題

衛生福利部雙和醫院 實證健康照護中心 譚家偉 主任

緣起…



Prognostic Factors in Node-Negative Breast Cancer

A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years

Table 14. RECOMMENDATIONS FOR PROGNOSTIC FACTORS IN BREAST CANCER

Prognostic Marker	N	ode-Negative Breas	st Cancer	All Breast Cancer			
	All studies	MV studies*	MV studies (no systemic TX)†	CAP ⁴	ASCO ^{6,64}	AJCC ⁶⁵	
Tumor size	↑ (9)	↑ (4)	↑ (1)	1	22%	↑	
Histologic grade	↑ (6)	↑ (3)	↑ (1)	↑	, = 1	1	
ER	\rightarrow (7)	\rightarrow (4)	→ (4)	į.	\rightarrow	4	
p53	→ (16)	\rightarrow (12)	\rightarrow (4)	\rightarrow	1	1.50	
HER2/neu	→ (13)	↓ (6)	↓ (1)	\rightarrow	1	_	
Cathepsin-D	↑ (4)	↑ (2)	↑ (2)	1	1	-	
Ki-67	↑ (5)	↑ (5)	↑ (2)	\rightarrow	3 3	1	
DNA ploidy	↓ (4)	↓ (4)	↓ (2)	1	1	į	
S-phase	↑ (5)	↑ (4)	\rightarrow (2)	\rightarrow		†	
Mitotic index	↑ (4)	↑ (1)	-	1	-	†	
Vascular invasion	↑ (5)	↑ (4)	↑ (2)	†	2 5	†	

^{↑:} Usefulness as prognostic factor supported by multiple studies; →: Mixed results; ↓: Not recommended as prognostic factor; preponderance of studies give negative results. Number of reports identified meeting study criteria are given in parentheses.

^{*} MV: studies in which multivariate analysis was used to assess the validity of the marker as a prognostic factor for survival.

[†] MV (no systemic TX): studies in which multivariate analysis was used and in which patients received no systemic therapy.

2009年考科藍系統性文獻回顧工作坊

Fahad Javaid Siddiqui Edwin Chan



Singapore Branch, Australasian Cochrane Centre

Perform a Meta-analysis

- Download software
- Focus a good question
- Selection criteria
- Search strategy
- Study selection and data extraction
- Assess methodological quality
- Statistical Analysis
- Discussion

Focus a good question


- Foreground question
- Therapy/Diagnosis/Prognosis/Etiology/Harm
- Tips:
 - 從Therapeutic question開始第一篇SR
 - 當臨床上有不同意見時,就PubMed一下吧
 - 從小到大



Outcomes of Staple Fixation of Mesh Versus Nonfixation in Laparoscopic Total Extraperitoneal Inguinal Repair: A Meta-Analysis of Randomized Controlled Trials

Ka-Wai Tam · Hung-Hua Liang · Chiah-Yang Chai

	No fixa	tion	Staple fix	ation		Odds Ratio			0		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-l	<u> 1, Fixed, 9</u>	5% CI	
Ferzli 1999	0	50	1	50	2.1%	0.33 [0.01, 8.21]			•		
Koch 2006	2	27	10	26	13.5%	0.13 [0.02, 0.66]		•			
Lau 2003	14	100	20	100	24.6%	0.65 [0.31, 1.38]			-		
Moreno-Egea 2004	14	85	18	85	21.5%	0.73 [0.34, 1.59]			-		
Parshad 2005	4	34	2	29	2.7%	1.80 [0.31, 10.62]			- •		
Taylor 2008	27	250	28	250	35.7%	0.96 [0.55, 1.68]			•		
Total (95% CI)		546		540	100.0%	0.73 [0.51, 1.05]			•		
Total events	61		79								
Heterogeneity: Chi ² = 6	6.55, df = 5	5(P = 0)	.26); l ² = 2 ⁴	1 %			0.04			10	4.0
Test for overall effect:	Z = 1.70 (F	P = 0.09	9)				0.01 Favo	0.1 urs no fix	1 ation Fav	10 ours stapl	10 e fixa







A list from PubMed search

David	2009	Lancet	RCT	Stapl	e vs	NF
-------------------------	------	--------	-----	-------	------	----

- Peter 2008 NEJM RCT Staple vs NF
- John 2006 JAMA RCT Staple vs NF
- Mary 2006 BMJ RCT Staple vs Glue
- Anna 2005 BMJ RCT Glue vs NF
- Susan 2004 WJS Prosp. Staple vs NF
- Paul 1999 BJS Retro. Staple vs NF



Systematic Review of the Use of a Mesh to Prevent Parastomal Hernia

Ka-Wai Tam · Po-Li Wei · Li-Jen Kuo ·

Chih-Hsiung Wu





 Table 1
 Seven clinical studies describing parastomal hernia prophylaxis by mesh placement

Author	Study design	Number of Patients	Follow-up (months)	Operative techniq	ue Mesh
Jänes [2009]	RCT	Mesh: 27 No mesh:27	Mean: 65.2 Range: 57-83	Sublay	Large-port lightweight polypropylene + polyglactin 910 (Vypro)
Serra-Aracil [2009] RCT	Mesh: 27 No mesh: 27	Median: 29 Range: 13-49	Sublay	Large-port lightweight polypropylene + polyglecaprone 25 (Ultrapro)
Hammond [2008]	RCT	Mesh: 10 No mesh: 10	Median: 6.5 Range: 1-12	Sublay	Procine-derived cross- linked collagen implant (Permacol)
Berger [2008]	Prospective	Mesh: 25	Means: 11 Range:2-19	Intraperitoneum Onlay	Polyvinylidere + polypropylene (Dynamesh IPST)
Vijayasekar [2008]] Prospective	Mesh: 42	Mean: 31 Range: 9-68	Sublay	Polypropylene (Auto Suture)
Gögenur [2006]	Prospective	Mesh: 24	Median 12 Range: 2-26	Onlay	Polypropylene (StomaMesh)
Bayer [1986]	Retrospective	e Mesh: 36	Up to 48	Onlay	Polypropylene (Marlex)

Flowchart for selection of trials



Ligasure vessel-sealing system or harmonic scalpel versus conventional vessel ligation for thyroidectomy (Protocol)


Tam KW, Chan ESY, Chen C






The fruit is ripe

Manual lymphatic drainage for lymphedema





Effects of manual lymphatic drainage on breast cancer-related lymphedema: a systematic review and meta-analysis of randomized controlled trials

World Journal of Surgical Oncology 2013, 11:15

Table 1 Characteristics of studies that fulfilled the inclusion criteria for meta-analysis

Reference	Inclusion criteria	No. of patients	Age, years, (mean ± SD)	Intervention
Treatment				
Andersen, 2000	Symptoms of lymphedema; 20 mm circumference or 200 ml volume difference between arms	C: 22	C: 56 (29 to 77) ^a	C: Sleeve and glove compression 32 to 40 mmHg + exercises + skin care + safety precautions
		1: 20	l: 53 (25 to 73)	I: C + MLD 8 times in 2 weeks
Didem, 2005	2-50 mm circumference difference between arms; lymphedema > 12 months after surgery	C: 26	C: 54.7 ± 12.1	C: Bandaging; elevation; head, neck and shoulde exercise, 3 days/week for 4 weeks
		1; 27	l: 53.1 ± 3.05	I: C + MLD
Prevention				
Devoogdt, 2011	Patients after breast-cancer surgery	C: 81	C: 54.5 ± 11.1	C: Exercise therapy 30 minutes/session
		l: 77	l: 55.8 ± 12.5	I: C + MLD 30 minutes/session for 40 sessions
Torres Lacomba,	Patients after breast-cancer surgery	C: 60	C: 52.9 ± 12.5	C: Educational strategy
2010		1: 60	l: 52.9 ± 10.7	I: C + MLD + massage + exercise

Abbreviations: C, control; I, intervention; G, group; MLD, manual lymphatic drainage; SLD, simple lymph drainage; SPC, sequential pneumatic compression. Values are mean ± standard deviation, except for amean (range).



Table 1: Characteristics of the included studies

Peristomal Skin Care: A Systematic Review and Meta-analysis of RCTs




Table 1 Characteristics of studies that fulfilled the inclusion criteria of the meta-analysis

Study [year]	Study design	Inclusion criteria	No. of patients	Age (y), mean ± SD	Intervention
Interven	ition vs St	andard wound dressing			
Aschl	RCT	Percutaneous	C: 48	65 (5–91)*	C: Standard wound dressing × 1 wk
[2008]		endoscopic gastrostomy	I: 50		I: Glycogel dressing × 1 wk
Berg [2005]	RCT crossov er	Colostomy	C: 16	C: 63.8 ± 11.2	C: Grooved base-plate wafer adhesive-pouch coupling system \times 15 d then crossover
			I: 23	I: 65.4 ± 8.8	I: Gelatin/pectin-based skin barrier \times 15 d then crossover
Blume nstein,	RCT	Percutaneous endoscopic gastrostomy	C: 34	C: 61.5 ± 7.1	C: Dry gauze and adhesive breathable dressing × 4 wk
[2012]			I: 34	I: 60.5 ± 12.1	I: Glycerin hydrogel wound dressing × 4 wk
Hossei	RCT	Hirschsprung's	C: 30	C: 4.87 ± 2.13	C: 2.5% zinc sulfate ointment × 4 wk
npour, [2012]		enterocolitis or high imperforate anus, undergoing colostomy	1: 30	I: 5.32 ± 1.41	I: Acacia senegal fiber pockets × 4 wk
Park	RCT	Colostomy or ileostomy	C: 45	C:55.9 ± 11.6	C: Standardized peristomal skin care \times 3 mo
[2011]			I: 36	I: 56.8 ± 12.8	I: Crusting technique (hydrocolloid powder dusted on skin; powder sealed using watersoaked gauze) \times 3 mo
Treatme	nt for ski	n damage			
Charou	Quasi	Colostomy with	C: 36	C: 54.5 ± 5.53	Hydrocortisone 1% ointment, once daily
saei, [2011]	RCT	peristomal skin damage	I: 36	I: 54.9 ± 5.91	German chamomile compression, twice daily
*Median (rang	ge)				

Postoperative Nausea and Vomiting (PONV)



Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Thyroidectomy: Metaanalysis of Randomized Controlled Trials

Chia-Che Chen, Fahad Javaid Siddiqui, Ta-Liang Chen, Edwin Shih-Yen Chan & Ka-Wai Tam

World Journal of Surgery

Official Journal of the International Society of Surgery/Societé Internationale de Chinargie

ISSN 0364-2313 Volume 36 Number 1

World J Surg (2012) 36:61-68 DOI 10.1007/s00268-011-1343-9





PONV after thyroidectomy

- Incidence:
 - 75-80%
- Risk:
 - Sex
 - Middle-aged
 - Edema around neck tissues after surgery =>
 evoke vagal stimulation to the vomiting center



緣起: Journal Club

Randomized Controlled Trial on Single Dose Steroid Before Thyroidectomy for Benign Disease to Improve Postoperative Nausea, Pain, and Vocal Function

Mathias Worni, MD,* Hans H. Schudel, MS,* Eberhard Seifert, MD,† Roman Inglin, MD,* Matthias Hagemann, MD,† Stephan A. Vorburger, MD, MCR,* and Daniel Candinas, MD, FRCS*



Ann Surg. 2008; 248:1060-1066



Dexamethasone Combined with Morphine does not Decrease Postoperative Nausea and Vomiting in Patients Undergoing Thyroidectomy or Parathyroidectomy

Jong-Yueh Lin, Fong-Fu Chou, Ting-Lung Lin, Kun-Chou Hsieh, Ya-Ling Yang¹

Table 2. Main adverse effects after operation and rescue antiemetic requirements

	Gro	oup I	Group II
	Group A	Group B	
Number	N = 41	N = 39	N = 42
Nausea (none/mild/moderate/severe)			
4 h	21/5/8/7	11/4/12/12 *	10/4/15/13 †
24 h	32/4/4/1	28/7/1/3	31/12/4/0
Vomiting (times)			
4 h	1.1 ± 2.3	$2.8 \pm 3.4^{\ddagger}$	2.6 ± 3.0 §
24 h	0.3 ± 1.0	0.4 ± 1.1	0.4 ± 1.1
Wound pain (VAS score)			
4 h	5.9 ± 3.3	4.7 ± 3.6	4.6 ± 3.1
24 h	3.9 ± 2.6	3.3 ± 2.5	2.9 ± 2.7
Need of rescue medication within 24 h	2	4	5
Need of pethidine within 24 h (mg)	$54 \pm 36 (N = 7)$	$75 \pm 28 \text{ (N = 4)}$	$50 \pm 0 \text{ (N = 5)}$

Group I: Dexamethasone used before induction

Group A: No morphine used before the end of general anesthesia

Group B: Morphine (3-5 mg) used before the end of general anesthesia

Group II: Normal saline used before induction

Selection criteria

— Inclusion criteria:


- (1) Evaluate the prophylactic effect of dexamethasone compared with placebo or any other medications on PONV in patients undergoing thyroidectomy.
- (2) Clearly document the inclusion and exclusion criteria of patient selection.
- (3) Clearly document the anesthetic techniques and the protocol of administration of the experimental drugs.
- (4) Clearly document the definition and evaluation of nausea and vomiting.



– Exclusion criteria:


- (1) Patients enrolled in the trials were undergoing other surgical procedures concomitantly.
- (2) Dexamethasone administered via oral or rectal and not by intravenous route.
- (3) Outcomes of interest were not clearly reported.
- (4) Overlap between authors, centers or patient cohorts evaluated in the published literature.

Flowchart for selection of the trials




使用皮質類固醇激素預防全身麻醉病人術後噁心嘔吐的改善專案





Dexamethasone, ondansetron, and their combination and postoperative nausea and vomiting in children undergoing strabismus surgery: a meta-analysis of randomized controlled trials

Yun-Dun Shen¹, Chien-Yu Chen^{2,3}, Chih-Hsiung Wu^{4,5}, Yih-Giun Cherng^{6,7} & Ka-Wai Tam^{4,5,8,9,10}





下肢静脈曲張



一週或四週???

The Optimal Duration of Compression Therapy Following Varicose Vein Surgery: A Meta-analysis of Randomized Controlled Trials

T.-W. Huang ", S.-L. Chen ", C.-H. Bai b, C.-H. Wu c, K.-W. Tam d,e,fg.*

European Journal of Vascular and Endovascular Surgery Month/2013

Table 1. Characteristics of studies fulfilling inclusion criteria in the meta-analysis.

Author [year]	Inclusion criteria	Surgery	No. of patients (leg)	Age (year, mean ± SD)	Intervention
Biswas [2007]	Primary varicose vein surgery for SFJ/GSV reflux	Ligation and stripping of the GSV and multiple phlebectomies	S: 110 L: 110	S: 48 ± 19 L: 47 ± 19.5	S: 3 days elastic bandages + 1 week TED stockings L: 3 days elastic bandages + 3 weeks TED stockings (Kendall TED stockings, Tyoc Healthcare, Hants PO13 OAS)
Houtermans-Auckel [2009]	CEAP stage C2 or C3	Ligation and stripping of the GSV and multiple phlebectomies	S: 52 L: 52	S: 49 ± 11 L: 50 ± 13	5: 3 days elastic bandages L: 3 days elastic bandages + 4 weeks stockings (23–32 mmHg; 2 weeks day and night, 2 weeks day only)
Raraty [1999]	N/A	Saphenous ligation, sequential avulsion of the GSV and multiple stab avulsions	S: 53 (64) L: 52 (67)	5: 49.2 (20-75) [†] L: 51.5 (16-72) [†]	S: 1 week elastic bandages L: 16 h crepe bandages + 6 weeks TED stockings (1 week day and night, 5 weeks day only)
Rodrigus [1991]	N/A	Stripping of the GSV and multiple phlebectomies	S: (84) L1: (84) L2: (89)	N/A	S: 1 week elastic bandages L1: 1 week elastic bandages + 2 weeks tubegauze L2: 1 week elastic bandages + 5 weeks tubegauze (Tubigrip; Seton)



Original Investigation


Regional Citrate Versus Heparin Anticoagulation for Continuous Renal Replacement Therapy: A Meta-Analysis of Randomized Controlled Trials


Mei-Yi Wu, MD, 1 Yung-Ho Hsu, MD, 1 Chyi-Huey Bai, PhD, 2 Yuh-Feng Lin, MD, 1 Chih-Hsiung Wu, MD, PhD, 3 and Ka-Wai Tam, MD, MS4


	Citrat	Citrate Heparin				Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Rand	fom, 95% CI	
Betjes	2	21	0	27	13.7%	6.36 [0.32, 125.86]		•	
Hetzel	1	87	0	83	12.0%	2.86 [0.12, 69.32]	<u> </u>		
Kutsogiannis	1	16	0	14	12.5%	2.65 [0.12, 60.21]	103	2	
Monchi	1	8	0	12	12.8%	4.33 [0.20, 94.83]	89		
Oudemans-van Straaten	6	97	2	103	49.0%	3.19 [0.66, 15.41]	40	8 8	
Total (95% CI)		229		239	100.0%	3.51 [1.17, 10.60]		•	
Total events	11		2					322 50	
Heterogeneity: Tauz = 0.00); Chi² = 0.	23, df =	4 (P = 0	.99); 12	= 0%				
Test for overall effect: Z =			92970 A	(0.00000)			0.01 0.1 Favours citrate	1 10 100 Favours heparin	

Figure 5. Forest plot of comparison: citrate versus heparin. Outcome: incidence of hypocalcemia. Abbreviation: CI, confidence interval.









Systematic Review of Clinical Practice Guidelines in the Diagnosis and Management of Thyroid Nodules and Cancer

Tsai-Wei Huang, RN, PhD¹; Jun-Hung Lai, MD^{1;2}; Mei-Yi Wu, MD^{3,4}; Shiah-Lian Chen,RN, PhD¹; Chih-Hsiung Wu, MD, PhD^{5,6}, Ka-Wai Tam, MD, MSc^{4,5,6,7,8,9}

Table 2. Domain scores (%) of the 10 clinical practice guidelines assessed using the AGREE-II instrument

Domain	AACE/A ME/ETA [2010]	ATA [2009]	BTA [2007]	ESMO [2012]	GAES [2013]	IKNL [2007]	LATS [2009]	NCCN [2013]	NCN [2000]	SEOM [2011]
Domain 1:	76.4	84.7	87.5	33.3	61.1	87.5	79.2	79.2	68.1	40.2
Scope and purpose										
Domain 2:	65.2	72.2	76.4	22.2	54.2	75	44.4	69.4	51.4	26.4
Stakeholder involvement										
Domain 3:	62.5	61.98	66.1	21.4	58.9	88.5	45.8	58.3	36.4	16.1
Rigor of development										
Domain 4:	77.8	70.8	69.4	38.9	63.9	73.6	54.2	81.9	56.9	45.8
Clarity of presentation										
Domain 5:	38.5	42.7	56.3	22.9	35.4	63.5	40.6	57.2	29.2	21.9
Applicability										
Domain 6: Editorial independence	79.2	81.3	75	39.6	45.8	79. <mark>2</mark>	52.1	85.4	29.2	33.3

Recommendations	AACE/	ATA [2009]	BTA [2007]	ESMO	GAES	IKNL	LATS	NCCN	NCN	SEOM
	AME/ ETA [2010]			[2012]	[2013]	[2007]	[2009]	[2013]	[2000]	[2011]
Diagnosis		ee at	201 - Tet							
Indications of fine-needle aspiration (without suspicions)	n > 1 cm	n > 0.5 cm	n > 0.5 cm	n > 1 cm	All nodules	All nodules	N/A	n > 1.5 cm	All nodules	n > 1 cm
Routine serum calcitonin	Optional	NR	N/A	R	R	R	Optional	Optional	Optional	R
Thyroid scan	Low TSH	Follicular lesion with low TSH	N/A	Unclear	Before operation	NR	N/A	Follicular lesion with low TSH	Unclear	NR
Treatment										
Indication of total thyroidectomy for DTC	N/A	n > 1 cm	n > 1 cm	n > 1 cm	n > 1 cm	n > 1 cm	All sizes	n > 4 cm	n > 1cm	n > 4 cm
Cervical lymph node dissection (node negative) Postoperative care	N/A	n > 4 cm	n > 4 cm/male/ age > 45 y	Optional	Optional	N/A	n > 4 cm	Optional	Unclear	Optional
Indication of I ¹³¹ ablation	N/A	n > 4 cm/ high-risk patients	High-risk patients	n > 2 cm/ high-risk patients	N/A	High- risk patients	High- risk patients	Tg > 1 ng/mL/ high-risk patients	n > 1 cm	High-risk patients
Target level of TSH suppression therapy (mU/L)								■ 000000000000000000000000000000000000		
High risk	N/A	<0.1	<0.1	<0.1	N/A	<0.1	<0.1	<0.1	0.01 to 0.1	<0.1
Low risk	N/A	0.1 to 0.5	0.1 to 0.5	WNL	N/A		0.4 to 1.0	Close to the lower limit		<0.1 to 0.5

DTC, differentiated thyroid cancer; I, iodine; n, nodule; N/A, not available; NR, not recommended; R, recommended; Tg, thyroglobulin; TSH, thyroid stimulating hormone; WNL, within normal limit.

Huang et al. BMC Medicine 2013, 11:191 http://www.biomedcentral.com/1741-7015/11/191



RESEARCH ARTICLE

Open Access


Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer

Tsai-Wei Huang¹, Jun-Hung Lai^{1,2}, Mei-Yi Wu^{3,4}, Shiah-Lian Chen¹, Chih-Hsiung Wu^{5,6} and Ka-Wai Tam^{4,5,6,7,8,9*}

Lithium toxicity profile: a systematic review and

meta-analysis

Lancet 2012 Feb 25;379(9817):721-8



Sigmoid Diverticulitis A Systematic Review

JAMA. 2014;311(3):287-297.

Figure. Clinical Outcomes Based on Current Treatment Standards for a Hypothetical Cohort of 1000 Patients Presenting With Acute Diverticulitis




Table 2. Level of Recommendation for Systematic Review of Recent Literature Compared to Current Practice Guidelines for Prevention of Recurrent Sigmoid Diverticulitis

		Recommendation	
Intervention	Current Evidence Review and Guidelines ^a		Class
Recovered From 1 or More	Uncomplicated Episode		
Fiber supplementation		C	lla
Evidence review	Not addressed.		
Practice guidelines ^c	Long-term fiber supplementation may prevent recurrence (ASCRS)		
Antibiotic use		Α	Ш
Evidence review	For acute uncomplicated diverticulitis, a Cochrane review, 42,51 a systematic review, 44 and a retrospective cohort study 46 do not support use of antibiotics for prevention of recurrence		
Practice guidelines ^c	Not addressed		
Probiotics		C	IIb
Evidence review	A trial of 83 patients randomized to receive oral polybacterial lysate vs placebo reported no significant difference in recurrence rates $(P = .2 \text{ using } \chi^2 \text{ comparison of proportions})^{45}$		
Practice guidelines ^c	Not addressed		
Mesalamine		В	lla
Evidence review	Small uncontrolled trials indicate approximately 3% recurrence rate over 1 y with use of combined mesalamine and rifaximin ⁵²		
Practice guidelines ^c	Not addressed		
Avoiding nuts and seeds		Α	111
Evidence review	A survey of 47 228 health professionals reported that incident diverticulitis was not associated with nut, corn, or popcorn ingestion and that increased nut intake was associated with lower risk of diverticulitis ²¹		
Practice guidelines ^c	Not addressed		

Table 2. Level of Recommendation for Systematic Review of Recent Literature Compared to Current Practice Guidelines for Prevention of Recurrent Sigmoid Diverticulitis (continued)

		Recommendation ^b	
Intervention	Current Evidence Review and Guidelines ^a		Class
Young Patients (≤50 y)			
Surgical resection		С	llb
Evidence review	Several cohort studies found modestly higher rates of recurrence among patients younger than 40 y than among those older than 40 y ^{71,72,85,86} ; however, these data were countered by other cohort studies that did not document a more aggressive disease course based on age ⁸⁷⁻⁹³		
Practice guidelines ^c	The decision to recommend elective sigmoid colectomy after recov- ery from acute diverticulitis should be made on a case-by-case basis (ASCRS)	В	(1)
	There is no clear consensus regarding whether younger patients (<50 y) are at increased risk of complications; however, they are probably at increased risk of recurrent diverticulitis (ASCRS)	С	lla
	In young patients with no comorbid conditions, elective surgery af- ter a single episode of diverticulitis is still a reasonable recommen- dation (WGO)	С	lla
	Elective sigmoid resection may not be necessary after any specific number of episodes of uncomplicated diverticulitis or with any definite age thresholds (SSAT)		


Individual patient data

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

[Repositive disease]
[CR. positive disease]
[CR. posit

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)*

Lancet 2011; 378:771-84



Second generation endometrial ablation techniques for heavy menstrual bleeding: network meta-analysis




Table 2 Amenorrhoea rate at 12 months: results from direct comparisons and network meta-analysis. Figures are odds ratios (95% confidence intervals) for device in column compared with device in row. Odds ratio >1 indicate increased rate with device in column

	Thermal balloon	Bipolar radio frequency	Microwave	Cryoablation	Free fluid	Laser	
First ger	neration device						
Direct	0.72 (0.52 to 1.01); P=0.06*	1.27 (0.73 to 2.20); P=0.4†	1.28 (0.90 to 1.83); P=0.2‡	0.30 (0.17 to 0.55); P<0.001†	0.57 (0.33 to 0.96); P=0.03†	4.88 (2.17 to 11.00); P<0.001†	
Network	0.69 (0.49 to 0.97); P=0.03	1.73 (1.07 to 2.78); P=0.03	1.14 (0.73 to 1.79); P=0.5	0.35 (0.17 to 0.75); P=0.01	0.62 (0.34 to 1.13); P=0.1	4.36 (1.82 to 10.44); P=0.002	
Thermal	balloon						
Direct		4.56 (2.24 to 9.26); P<0.001*	1.13 (0.70 to 1.82); P=0.6†	NA	NA	NA	
Network	la st	2.51 (1.53 to 4.12); P<0.001	1.66 (1.01 to 2.71); P=0.05	0.51 (0.23 to 1.17); P=0.1	0.91 (0.48 to 1.73); P=0.7	6.34 (2.50 to 16.07); P<0.001	
Bipolar	radio frequency						
Direct	()	_	NA	NA	0.36 (0.18 to 0.73); P=0.005†	NA	
Network	10 21	23	0.66 (0.36 to 1.21); P=0.2	0.20 (0.09 to 0.49); P=0.002	0.36 (0.19 to 0.67); P=0.004	2.52 (0.95 to 6.71); P=0.06	
Microwa	ive						
Direct	S 27	200	_	NA	NA	NA	
Network		2	<u></u>	0.31 (0.13 to 0.74); P=0.01	0.55 (0.27 to 1.13); P=0.09	3.82 (1.46 to 10.01); P=0.009	
Cryoable	ation						
Direct	-		-		NA	NA	
Network	(<u>←</u>)(<u>122</u>	<u></u>	222	1.77 (0.69 to 4.58); P=0.2	12.37 (3.96 to 38.59); P<0.001	
Free flui	d					100000000000000000000000000000000000000	
Direct	8		=	200	a - .5	NA	
Network	-	=	=		 :	6.98 (2.48 to 19.69); P<0.001	

My disappointed experiences

Systematic review and meta-analysis of studies of the timing of tracheostomy in adult patients undergoing artificial ventilation

OBSTETRICS

Staples vs subcuticular sutures for skin closure at cesarean delivery: a metaanalysis of randomized controlled trials

Effectiveness of a gentamicin impregnated collagen sponge on reducing sternal wound infections following cardiac surgery: a meta-analysis of randomised controlled trials

Factors

Success

- Interested or important issues
- Clinical diversity
- Malpractice issues
- Uncertain treatment protocol
- Suitable amount of trials with appropriate study design
- Enough data for analysis

Failure

- Well known issues
- Issues lack of clinical value
- Lack of primary research
- Lot of low quality papers
- Recent review published
- Compare apple to orange
- Incomparable outcome


Contrast-induced nephropathy (CIN)

- The effectiveness of N-acetylcysteine in preventing CIN in patients undergoing angiography?
- The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography?

The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials

Mei-Yi Wu · Hui-Fen Hsiang · Chung-Shun Wong · Min-Szu Yao · Yun-Wen Li · Chao-Ying Hsiang · Chyi-Huey Bai · Yung-Ho Hsu · Yuh-Feng Lin · Ka-Wai Tam

Flowchart for the selection of the studies



Thank you for your attention!